Cognis buys stake in Intermed naturals
This article was originally published in The Rose Sheet
Executive SummarySpecialty chemicals supplier Cognis has acquired an interest in, and signed a cooperation agreement with, InterMed Discovery GmbH, firm announces March 3. Move will allow Cognis to strengthen its portfolio of natural-source products, as InterMed has "one of the largest proprietary collections of biologically-active natural substances and extracts," chemical supplier says. "The combination of InterMed Discovery's natural product data and active ingredients with Cognis' know-how and market expertise in nutrition and cosmetics creates a unique platform for the development of new, innovative products and thus strengthens our market position," Norbert Weitkemper, Cognis' director of strategic business development, nutrition and health, says...
You may also be interested in...
Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.
Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.